Maximus provides a different starting point from a service that simply lists conventional tablet examples. Its Blood Flow page names a vardenafil–tadalafil combination and explicitly describes compounded prescription medicines. That makes the finished preparation, rather than recognition of either ingredient, the central question in a formulation review.
We reviewed the Blood Flow offer, relevant safety information and program terms on September 29, 2026. The public description supports a compounded offer, but it does not verify a selected liquid, suspension or individual dispensing pharmacy. The pages also contain differing alpha-blocker cautions, which this review preserves rather than attempting to resolve for a patient.
The named combination is not the whole specification
The Blood Flow offer includes a vardenafil-plus-tadalafil option. That identifies active ingredients presented together in the offer, but not every attribute of the finished preparation. It does not, in the reviewed description, establish the selected physical form, manufacturer or complete inactive-ingredient information.
The FDA glossary describes a drug product as a finished dosage form containing its ingredients. Under that distinction, two ingredient names are meaningful evidence without being a complete product identity. Calling the option a suspension would add a fact that the reviewed offer does not establish. This review therefore leaves the form unresolved instead of assigning it from the site's category.
Compounding is expressly disclosed
Maximus states that these medicines are compounded and are not FDA-approved or evaluated by FDA for safety, effectiveness or quality. Its own disclosure is consistent with the general regulatory distinction in FDA's compounding questions and answers: compounded drugs do not undergo the approval process for finished products.
This is not a finding about an individual batch or an allegation that a pharmacy violated a rule. It means that the approval of an ingredient-containing medicine elsewhere cannot establish approval of this particular combination. The ingredient-versus-product evidence guide explains why a formulation comparison needs to preserve that difference even when the ingredient names are familiar.
The pharmacy claim needs its own boundary
The offer page says medication is compounded by a licensed US pharmacy under a physician's prescription. We report that as Maximus's description. This review did not independently identify or verify the pharmacy that would dispense an individual reader's preparation, and the general statement does not supply a selected product label.
The pharmacy questions guide separates a provider's published assurance from the identity on dispensing documents. GoodRx Care's approval claim is a useful contrast in documentary categories: one offer expressly discusses compounding, while the other advertises FDA-approved medication. Neither headline alone identifies every feature of a specific supplied medicine.
Different safety wording should remain visible
The Blood Flow offer initially advises caution concerning alpha-blockers, while another passage on the same page gives a broader exclusion. The separate Blood Flow safety information uses a qualified restriction involving whether alpha-blocker treatment has been stabilized. These statements are not identical.
A review should not select whichever version makes the offer appear easier to access. Nor can this difference be settled by applying an unrelated medicine's label to an unknown compounded preparation. This is a source inconsistency for the responsible clinician to clarify against the actual proposed product and medical history, not a personal clearance rule or instructions for changing any medication.
Another Maximus program is not evidence for this one
The general terms include a section describing regular visits, prescription medication and shipping within the Testosterone Protocol. Those are program-specific statements. They cannot be used to fill missing details about Blood Flow's selected preparation, follow-up arrangement or included services merely because the company name is the same.
That separation matters for product identity as well as payment. A service agreement for one treatment category does not identify the formulation dispensed under another. This review therefore uses the Blood Flow page for its actual named combination and compounding disclosure, while leaving unverified individual arrangements open. It does not transfer another program's benefits or obligations into the ED offer.
A familiar ingredient does not close the evidence gap
FDA explains that it does not verify compounded medicines' safety, effectiveness and quality before marketing through the drug-approval process. Its compounding guidance addresses the finished compounded product, not merely whether one ingredient appears in an approved medicine somewhere else. That is the relevant boundary when interpreting this offer.
Optum Perks' clinical-service description provides a different comparison: it documents assessment without verifying a selected formulation. Both reviews need precise unknowns, although the known facts differ. For Maximus, compounding is stated; for the individual product, physical form and pharmacy identity remain unverified. Neither evidence gap supports a claim of superior results.
What can be concluded without inventing the form
The Blood Flow page establishes an advertised compounded option with named ingredients and a physician-prescription/pharmacy description. It does not establish that a selected preparation is a liquid or suspension. Its safety passages also leave a documented inconsistency that an independent review should not conceal.
The liquid and tablet comparison is useful only if these facts remain attached to the actual offer. Maximus can be described as a compounded-treatment service without assigning an unverified form or borrowing approval from a different product. A complete individual product record would need more than the combination name and the company's broad quality assurances.
Source records
These records have different purposes. A provider page documents its public wording; it does not independently verify a supplied product, a patient result or the service behind the claim.
- Maximus: Blood Flow offerOfficial compounded offer, named vardenafil–tadalafil combination and attributed licensed-US-pharmacy claim; physical form and individual pharmacy unverified. Alpha-blocker wording differs within the page and from the safety page. · Checked 2026-09-29
- FDA: Drugs@FDA glossaryPrimary definitions of dosage form, finished drug product and pharmaceutical equivalence; terminology does not verify any provider’s product or authorize preparation changes. · Checked 2026-09-29
- FDA: compounding questions and answersPrimary explanation of compounded drugs and absence of FDA finished-product approval; not an individual pharmacy violation, product-quality finding or patient recommendation. · Checked 2026-09-29
- Maximus: Blood Flow safety informationOfficial program-specific safety passages; qualified alpha-blocker wording differs from the offer. Not a selected-product label or personal clearance rule; no dose or administration instructions reproduced. · Checked 2026-09-29
- Maximus: terms of useOfficial terms containing separate program provisions; Testosterone Protocol inclusions do not establish Blood Flow services or a selected formulation. · Checked 2026-09-29